Citations

Clear

1526 citation(s) found for "Sun, Yu".

High Glucose Variability in Hospitalized Patients with Type 1 Diabetes Mellitus
Dadlani, Vikash, Tamhane, Shrikant , Sun, Ai-dong, Sharma, Anu , Delivanis, Danae A. , Thapa, Prabin , Carter, Ricky E., Kudva, Yogish C. , Carter, Rickey E. , Tamhane, Shrikant U, Sun, Aidong, Carter, Rickey E

Mayo Clinic

Diabetes Technology & Therapeutics | October 18, 2017 | Volume: 19 | Issue: 10 | Pages: 572-579

10.1089/dia.2017.0107 | PMID 29045170 Get It

Background: Glucose variability (GV) has been increasingly (or more extensively) studied in patients with type 1 diabetes (T1D) in the ambulatory setting; limited data exist on GV in hospitalized patients with T1D. Materials and Methods: Retrospective single center cohort study, we analyzed in-hospital glucose measurements to assess GV in 736 hospitalized patients in different units over a consecutive 5-year period of time. GV was assessed by mean blood glucose (BG), Average daily risk range (ADRR), high BG index, and low BG index. To place our findings in context, we conducted a systematic review using Cochrane collaboration methodology to critically analyze current published literature on GV in hospitalized T1D patients. Results: Overall, glycemic control was suboptimal with mean BG 183 ± 51.5 mg/dL and mean ADRR 35 with only 16% patients being categorized as low risk (ADRR <20) for hypo or hyperglycemia. Patients admitted in medical units had mean BG of 194.4 ± 42.8 mg/dL (95% CI = 101.2–346.6) and ADRR of 39.4 ± 16 (95% CI = 1.3–118.7), which were higher than the patients admitted in the surgical units (mean BG 168.1 ± 35.7 (95% CI = 74.8–301.8) and mean ADRR (28.8 ± 13.1 [95% CI = 0.3–93.1]). For the systematic review, initial search yielded 2336 studies for screening, however, none of them had data specific for T1D. Conclusion: GV is high in hospitalized T1D patients admitted at our tertiary care center. Review of the literature shows paucity of data regarding GV in hospitalized patients with T1D.
More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma
Jun, Tomi , Yang, Ju Dong , Chen, Vincent , Nguyen, Pauline, Giama, Nasra H., Huang, Chung‐Feng , Hsing, Ann W. , Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Nguyen, Mindie H , Roberts, Lewis R , Chen, V L , Yu, M-L , Yeh, Ming-Lun , Yang, Ju Dong , Dai, Chia-Yen , Huang, Jee‐Fu

Mayo Clinic

Liver International | October 16, 2017 | Volume: 38 | Issue: 5 | Pages: 895-902

10.1111/liv.13613 | PMID 29045023 Get It

AbstractBackground & AimsAlthough hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major risk factors for hepatocellular carcinoma (HCC), non‐viral causes of HCC, particularly non‐alcoholic fatty liver disease (NAFLD), are becoming increasingly prevalent. The aim of this study was to compare the clinical characteristics and survival of cryptogenic and viral HCC.MethodsWe conducted a retrospective cohort study involving 3878 consecutive HCC patients seen at two tertiary centres in the United States and one in Taiwan from 2004 to 2014. We compared the clinical characteristics, treatment and survival of patients by underlying aetiology: cryptogenic (n = 696), HBV (n = 1304) or HCV (n = 1878).ResultsCirrhosis was present in 66.8% of the cryptogenic HCC patients, compared with 74.7% of HBV‐related HCC (HBV‐HCC) (P = .001) and 85.9% of HCV‐HCC (P < .001). Compared to viral HCC, cryptogenic HCC patients presented with larger tumours and at later stages of disease. Five‐year overall survival was 16.3% among cryptogenic HCC patients compared with 31.9% among HBV‐HCC patients and 27.7% among HCV‐HCC patients (P < .001 for both by the log‐rank test). HCC aetiology was not an independent predictor of survival, though ethnicity, cirrhosis status, meeting Milan criteria and treatment allocation were.ConclusionsCompared with viral HCC patients, those with cryptogenic HCC had lower prevalence of cirrhosis, were diagnosed with larger tumours at more advanced stages of disease, and had poorer overall survival. Additional efforts are needed to identify patients at risk of cryptogenic HCC and to identify cryptogenic HCC at earlier stages of disease.
Lactic Acid: No Longer an Inert and End-Product of Glycolysis
Sun, Shiren , Chen, Jianghua , Qian, Qi , Li, Heng

Mayo Clinic

Physiology | October 12, 2017 | Volume: 32 | Issue: 6 | Pages: 453-463

10.1152/physiol.00016.2017 | PMID 29021365 Get It

For decades, lactic acid has been considered a dead-end product of glycolysis. Research in the last 20+ years has shown otherwise. Through its transporters (MCTs) and receptor (GPR81), lactic acid plays a key role in multiple cellular processes, including energy regulation, immune tolerance, memory formation, wound healing, ischemic tissue injury, and cancer growth and metastasis. We summarize key findings of lactic acid signaling, functions, and many remaining questions.
The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors
Sun, Yu , Lohse, Christine M. , Smyrk, Thomas C. , Hobday, Timothy J. , Kroneman, Trynda, Zhang, Lizhi , Hobday, Timothy

Mayo Clinic

American Journal of Surgical Pathology | October 10, 2017 | Volume: 42 | Issue: 2 | Pages: 247-255

10.1097/pas.0000000000000968 | PMID 29016403 Get It

Tumor cell proliferation rate determined by either Ki-67 index or mitotic count (MC) has shown to be a prognostic factor for gastrointestinal neuroendocrine tumors in general, and after its incorporation in the 2010 World Health Organization tumor grading system, it has become essentially mandatory in pathology reports for all gastrointestinal neuroendocrine tumors, regardless of tumor location. Nevertheless, clinical significance for the Ki-67 index or MC has not been well demonstrated in small intestinal neuroendocrine tumor (SINET), especially those without distant metastasis, the majority of which have very low proliferation rates. We assessed the clinical behavior of 130 SINETs in relation to stage, Ki-67 index, MC, and other pathologic features. Most SINETs (86%) were grade 1 and 14% were grade 2. There were no grade 3 tumors or poorly differentiated neuroendocrine carcinomas. On multivariate analysis, age, Ki-67 index >5%, MC >10/50 high-power field, stage IV, and liver metastases were associated with increased risk of death in all patients. When both stage and grade were considered, Ki-67 index >5% was associated with a nearly 4-fold increased risk of death in stage IV cases (n=60). In contrast, Ki-67 index did not show prognostic value for patients with stages I to III disease (n=70), although MC >1/50 high-power field was significantly associated with death on multivariable analysis. Our study confirms that liver metastasis and increased tumor cell proliferation rate are independent prognostic factors for SINETs, but shows that most SINETs have a very low proliferation rate, which limits its value for predicting tumor behavior. By combining staging and grading information, we demonstrate different roles and cutoff values of Ki-67 index and MC in SINET with different stages.
Adipose tissue DNA methylome changes in development of new-onset diabetes after kidney transplantation
Baheti, Saurabh , Singh, Prachi , Zhang, Yun , Evans, Jared M., Jensen, Michael D. , Kocher, Jean‐Pierre , Sun, Zhifu , Chakkera, Harini A. , Evans, Jared, Sun, Zhifu , Somers, Virend K. , Singh, Prachi , Chakkera, Harini A

Mayo Clinic

Epigenomics | October 2, 2017 | Volume: 9 | Issue: 11 | Pages: 1423-1435

10.2217/epi-2017-0050 | PMID 28967791 Get It

Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma
Davila, Jaime , Starr, Jason S. , Attia, Steven , Knudson, Ryan A., Necela, Brian M. , Sarangi, Vivekananda , Sun, Zhifu , Ren, Yingxue , Casler, John D., Menke, David M. , Oliver, Gavin R. , Copland, John A. , Parker, Alexander S. , Kocher, Jean-Pierre A., Thompson, E. Aubrey , Smallridge, Robert C., Asmann, Yan W. , Davila, Jaime I, Sun, Zhifu , Davila, Jaime I , Wang, Chen , Joseph, Richard W.

Mayo Clinic

Rare Tumors | September 15, 2017 | Volume: 9 | Issue: 2 | Pages: 50-53

10.4081/rt.2017.6834 | PMID 28975018 Get It

We previously reported an extremely rare case of follicular dendritic cell sarcoma (FDCS) presented as a thyroid mass. Given the rarity of this disease, there are no personalized and molecularly targeted treatment options due to the lack of knowledge in the genomic makeup of the tumor. A 44-year-old white woman was diagnosed with an extranodal FDCS in thyroid. The patient underwent a total thyroidectomy, central compartment dissection, parathyroid re-implantation, and adjuvant radiation therapy. Tumor DNA sequencing of 236 genes by FoundationOne panel found truncating mutations in PTEN and missense mutations in RET and TP53. However, patient-matched germline DNA was not sequenced which is critical for identification of true somatic mutations. Furthermore, the FoundationOne panel doesn't measure genomic rearrangements which have been shown to be abundant in sarcomas and are associated with sarcoma tumorigenesis and progression. In the current study, we carried out comprehensive genomic sequencing of the tumor, adjacent normal tissues, and patient-matched blood, in an effort to understand the genomic makeup of this rare extranodal FDCS and to identify potential therapeutic targets. Eighty-one somatic point mutations were identified in tumor but not in adjacent normal tissues or blood. A clonal truncating mutation in the CLTCL1 gene, which stabilizes the mitotic spindle, was likely a driver mutation of tumorigenesis and could explain the extensive copy number aberrations (CNAs) and genomic rearrangements in the tumor including a chr15/chr17 local chromothripsis resulted in 6 expressed fusion genes. The fusion gene HDGFRP3→SHC4 led to a 200-fold increase in the expression of oncogene SHC4 which is a potential target of the commercial drug Dasatinib. Missense mutations in ATM and splice-site mutation in VEGFR1 were also detected in addition to the TP53 missense mutation reported by FoundationOne.
Paracrine Secretion of Transforming Growth Factor β by Ductal Cells Promotes Acinar-to-Ductal Metaplasia in Cultured Human Exocrine Pancreas Tissues
Liou, Geou‐Yarh , Yin, Xue, Liu, Chengyang , Sun, Lu‐Zhe , Störz, Peter , Wang, Pei , Akanuma, Naoki, Liou, Geou-Yarh , Akanuma, Naoki , Liu, Jun , Bejar, Kaitlyn

Mayo Clinic

Pancreas | September 11, 2017 | Volume: 46 | Issue: 9 | Pages: 1202-1207

10.1097/mpa.0000000000000913 | PMID 28902792 Get It

Objective We aimed to evaluate the contribution of acinar-to-ductal metaplasia (ADM) to the accumulation of cells with a ductal phenotype in cultured human exocrine pancreatic tissues and reveal the underlying mechanism. Methods We sorted and cultured viable cell populations in human exocrine pancreatic tissues with a flow cytometry–based lineage tracing method to evaluate possible mechanisms of ADM. Cell surface markers, gene expression pattern, and sphere formation assay were used to examine ADM. Results A large proportion of acinar cells gained CD133 expression during the 2-dimensional culture and showed down-regulation of acinar markers and up-regulation of ductal markers, assuming an ADM phenotype. In a serum-free culture condition, ADM induction was mainly dependent on transforming growth factor β (TGF-β) secreted from cultured ductal cells. Human acinar cells when cultured alone for a week in a serum-free condition do not undergo ADM. However, serum may contain other factors besides TGF-β to induce ADM in human acinar cells. In addition, we found that TGF-β cannot induce ADM of murine acinar cells. Conclusions Ductal cells are the major source of TGF-β that induces ADM in cultured human exocrine pancreatic tissues. This culture system might be a useful model to investigate the mechanism of ADM in human cells.
Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
Gerkin, Richard C. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Dugger, Brittany N. , Belden, Christine M. , Smith, Brian H. , Sue, Lucia I., Davis, Kathryn, Zamrini, Edward , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Annals of Clinical and Translational Neurology | September 8, 2017 | Volume: 4 | Issue: 10 | Pages: 714-721

10.1002/acn3.447 | PMID 29046880 Get It

AbstractObjectiveTo assess the predictive potential of the complete response pattern from the University of Pennsylvania Smell Identification Test for the diagnosis of Parkinson's disease.MethodsWe analyzed a large dataset from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete pattern of responses to all 40 items in each subject's test, we built predictive models of neurodegenerative disease, and we validated these models out of sample by comparing model predictions against postmortem pathological diagnosis.ResultsConsistent with anatomical considerations, we found that the specific test response pattern had additional predictive power compared with a conventional measure – total test score – in Parkinson's disease, but not Alzheimer's disease. We also identified specific test questions that carry the greatest predictive power for disease diagnosis.InterpretationOlfactory ability has typically been assessed with either self‐report or total score on a multiple choice test. We showed that a more accurate clinical diagnosis can be made using the pattern of responses to all the test questions, and validated this against the “gold standard” of pathological diagnosis. Information in the response pattern also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject, and not just the total score, both to enable more accurate diagnosis and to enable additional future insights.
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
Kim, Jung-Sun , Bamlet, William R. , Oberg, Ann L. , Chaffee, Kari G. , Donahue, Greg , Cao, Xing-Jun , Chari, Suresh T. , García, Benjamin A. , Petersen, Gloria M. , Zaret, Kenneth S. , Rabe, Kari G. , Kim, Jungsun , Chari, Suresh, Bamlet, William R , Cao, Xing-Jun , Chari, Suresh T

Mayo Clinic

Science Translational Medicine | August 31, 2017 | Volume: 9 | Issue: 398 | Pages: No page available

10.1126/scitranslmed.aah5583 | PMID 28701476 Get It

THBS2 and CA19-9 markers in human blood improve detection of pancreatic ductal adenocarcinoma.
Author response: NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma
Xiao, Zhijie , Zhu, Yun , Gao, Xuyuan , Tin, Vicky Pui‐Chi, Wong, Maria Pik , Liu, Jing , Wang, Siqi , Qin, Jing , Wang, Junwen , Wong, Maria Pik

Mayo Clinic

No container title available | August 24, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.26733.032 Get It